H3 G34-mutant high-grade glioma [PDF]
Brain Tumor Pathology, 2020 H3F3A G34 (H3.3 G34)-mutant high-grade gliomas (HGG) are rare, and newly recognized infiltrating gliomas of the cerebral hemisphere. Here, we report the clinicopathological and molecular characteristics of four H3.3 G34-mutant gliomas in terms of its biological behavior compared to those of glioblastomas (GBMs) and H3 K27M-mutant diffuse midline ...
Taemin Kim, Ka Young Lim, Woo Hyeon Lim
exaly +9 more sources
Multiscale Dynamical Scenario of High-mass Star Formation in an IRDC Filament G34
The Astrophysical Journal, 2023 There is growing evidence that high-mass star formation (HMSF) is a multiscale, dynamical process in molecular clouds, where filaments transport gas material between larger and smaller scales.
Sirong Pan, Hong-Li Liu, Sheng-Li Qin
doaj +4 more sources
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon [PDF]
npj Precision OncologyDiffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood.
Cameron Crowell +30 more
doaj +4 more sources
Rare Tumors, 2023 Diffuse hemispheric glioma, H3 G34-mutant, is a recently recognized distinct high-grade glioma with a dismal prognosis. In addition to the H3 G34 missense mutation, numerous genetic events have been identified in these malignant tumors, including ATRX ...
exaly +3 more sources
Integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34‐mutant reveals universal TP53 abnormalities [PDF]
Brain Pathology, Volume 36, Issue 4, July 2026.This integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34‐mutant expands the spectrum of associated genetic changes and underscores the presence of universal TP53 abnormalities at copy number, sequence, and protein expression level, with frequent yet largely unrecognized TP53 copy‐neutral loss of ...
Jorge A. Trejo‐Lopez +28 more
wiley +3 more sources
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant [PDF]
Neuro-OncologyAbstract Background Diffuse hemispheric glioma, histone 3 (H3) G34-mutant, has been newly defined in the 2021 World Health Organization (WHO) classification of central nervous system tumors. Here we sought to define the prognostic roles of clinical, neuroimaging, pathological, and molecular features ...
Emilie Le Rhun +38 more
core +8 more sources
G34, Another Connection between MYCN and a Pediatric Tumor [PDF]
Cancer Discovery, 2013 Abstract Summary: Recurrent mutations in H3F3A at K27 and G34 are frequent in pediatric glioblastoma, but it is unclear how these mutations promote tumorigenesis. In this issue of Cancer Discovery, Bjerke and colleagues identify mutations at G34 in H3F3A that result in elevated expression of MYCN as a potential mechanism in gliomagenesis.
Huang, Miller, Weiss, William A
openaire +6 more sources
Case Report: Evolutionary Clinical-Radiological Features of a Diffuse Hemispheric Glioma, H3 G34 Mutant with Over 5 Years of Survival [PDF]
Case Reports in Oncology, 2023 Diffuse hemispheric glioma (DHG), H3 G34 mutant was included in the 5th edition of the World Health Organization Classification of Tumors of the Central Nervous System recently published.
Camilla A.F. Yamada +6 more
doaj +2 more sources
Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults [PDF]
Neuro-Oncology Advances, 2021 Abstract Background Diffuse hemispheric gliomas, H3 G34-mutant (DHG H3G34-mutant) constitute a distinct type of aggressive brain tumors. Although initially described in children, they can also affect adults.
Thiébaud Picart +17 more
openaire +5 more sources
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response [PDF]
Acta NeuropatholPrevious studies have demonstrated poor outcomes in pediatric patients with H3 G34-mutant diffuse hemispheric glioma (DHG). However, the biological basis for this therapeutic resistance remains poorly understood.
Lin, Tong +18 more
core +4 more sources